Clinical efficasy of Montelukast-early-intervention for Japanese cedar pollinosis

Clinical efficasy of Montelukast-early-intervention for Japanese cedar pollinosis - Clinical efficasy of Montelukast for Japanese cedar pollinosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003105

Enrollment

150

Registered

2010-01-27

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

It is given montelukast 10mg, 1 capsule per 1 day, from a week before until the end of Japanese pollen season. It is given montelukast 10mg, 1 capsule per 1 day, from a week before until the end of J

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Being over class 2 in CAP-RAST against Japanese Cedar pollen over, and having clinicalsymptoms during Japanese cedar pollen season.

Exclusion criteria

Exclusion criteria: Pregnancy, potential pregnancy, and breas-feeding patient.

Design outcomes

Primary

Measure	Time frame
Effect of leukotriene antagonist	—

Secondary

Measure	Time frame
Nitric oxiside consentration in airway	—

Countries

Japan

Contacts

Public ContactTakechiyo Yamada

Faculty of Medicine, University of Fukui Ororhinolaryngology, Head and Neck Surgery

0776-61-8407

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026